Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 28

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

361

HTML

1824

Figures (1-2)

260

Tables (1-4)

233

Sum=2678

Jul 28, 2007 (publication date) through Feb 7, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

H Pylori

World J Gastroenterol. Jul 28, 2007; 13(28): 3836-3840
Published online Jul 28, 2007. doi: 10.3748/wjg.v13.i28.3836

Table 3 Eradication rate according to type of CYP2C19 polymorphism

HomoEM: homozygous-extensive metabolizer; HeteroEM: hetreozygous-extensive metabolizer; PM: poor metabolizer.

Citation: Hagiwara T, Kato M, Anbo T, Imamura A, Suga T, Uchida T, Fujinaga A, Nakagawa M, Nakagawa S, Shimizu Y, Yamamoto J, Takeda H, Asaka M. Improvement in symptoms after H₂-receptor antagonist-based therapy for eradication of H pylori infection. World J Gastroenterol 2007; 13(28): 3836-3840
URL: https://www.wjgnet.com/1007-9327/full/v13/i28/3836.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i28.3836